Eucrates Biomedical Acquisition Corp.

Eucrates Biomedical Acquisition Corp. (Nasdaq: EUCR) was a blank check company formed to pursue a business combination in the biomedical and life sciences sector. The company filed a Form 15-12G with the SEC on May 8, 2023, terminating its registration under Section 12(g) of the Securities Exchange Act and effectively ending its obligations as a public reporting company. The 15-12G filing marks the close of EUCR's life as a registered SPAC, a step that typically follows either the completion of a business combination or a liquidation and dissolution of the trust. Visit SpacDesk and sign up for full data, filings, and timeline analytics on EUCR and hundreds of other SPAC vehicles.